CRS-207: Completed Phase Ib enrollment

Aduro completed enrollment of 38 chemotherapy-naive patients with unresectable MPM in an open-label, U.S. Phase Ib trial evaluating CRS-207 in combination with pemetrexed and cisplatin. Patients are r...